MPV as a Predictor for ACS in Patients With MASLD
Key facts
- Where
- Sohag, EgyiptomSee the site
Where in Egyiptom
- Sohag University HospitalSohag, EgyiptomNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sohag University
- Trial code
- NCT07487571
- Record updated
- 2026. május 6.
- Original description
The aim of this study is to evaluate mean platelet volume (MPV) as a predictor of acute coronary syndrome (ACS) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD to evaluate mean platelet volume (MPV) as a predictor of acute coronary syndrome (ACS) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) in Sohag University Hospital.Read full original descriptionShow less
Mean Platelet Volume as a Predictor for Acute Coronary Syndrome in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease
The aim of this study is to evaluate mean platelet volume (MPV) as a predictor of acute coronary syndrome (ACS) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD to evaluate mean platelet volume (MPV) as a predictor of acute coronary syndrome (ACS) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) in Sohag University Hospital.
Inclusion: Adult patients aged ≥18 years; Confirmed diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD) based on clinical, laboratory, and imaging criteria); Patients diagnosed with acute coronary syndrome (unstable angina, NSTEMI, or STEMI) for Group I; MASLD patients without clinical or electrocardiographic evidence of acute coronary syndrome for Group II; Patients who provide informed consent to participate in the study.
Exclusion: Patients receiving antiplatelet or anticoagulant therapy prior to blood sampling; Patients with chronic liver diseases other than MASLD (e.g., viral hepatitis, autoimmune hepatitis, alcoholic liver disease); Patients with active infection, inflammatory diseases, or malignancy; Patients with chronic kidney disease or end-stage renal failure; Patients with known hematological disorders affecting platelet count or function; Pregnant or lactating females.